High-dose gammaglobulin therapy in four children with newly diagnosed insulin-dependent diabetes mellitus.
スポンサーリンク
概要
- 論文の詳細を見る
High-dose gammaglobulin therapy was administered to four children with newly diagnosed insulin-dependent diabetes mellitus as a clinical immunomodulation therapy trial. Approximately 400mg/kg/day of polyethylene glycol-treated intact gammaglobulin was intravenously injected for 4-5 days into our patients. Before and after the therapy, determinations were a made on the patients for serum C-peptide immunomeactivity (CPR), at two hours postprandially, and arginineimposed CPR reaction to estimate residual pancreatic beta cell function. The daily insulin dose requirement was calculated, glycosylated hemoglobin (HbA<SUB>1</SUB>) was determined, and immunological study was performed before and after the therapy. In all ptients CPR in serum was significantly increased, and half of them showed higher CPR res ponse to arginine administration after the introduction of high-dose gammaglobulin therapy. Insulin dose requirement was markedly decreased, and three of four patients are now controlled with a dose of less than 0.5u/kg/day insulin six months or more after onset. The evidence suggests that high-dose gammaglobulin therapy prevents decline of pancreatic beta cell function and provides prolongation of partial remission with excellent glycemic control.
- 一般社団法人 日本糖尿病学会の論文
一般社団法人 日本糖尿病学会 | 論文
- Hyperlipidemia and Analysis of the Use of Lipid-lowering Drugs in Non-insulin-dependent Diabetes Mellitus.
- Thyrotoxic Crisis in a Patient with Mitochondrial Diabetes Mellitus.
- Rapidly Progressive Nephropathy in a Young Patient with Mitochondrial Gene Mutation.
- An Autopsy Case of Ketoacidosis in Insulin Dependent Diabetes Mellitus Patient Complicated with Adult Respiratory Distress Syndrome, DIC and Leukopenia.
- Studies on Alcoholic Beverages in Relation to Body Weight for Mild Diabetics